Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,885 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,373)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02718833 | A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma | active not recruiting | Phase 2 | 52 | Massachusetts General HospitalOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04586426 | A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma(RedirecTT-1) | active not recruiting | Phase 1 / Phase 2 | 228 | Janssen Research & Development, LLCINDUSTRY | 7 |
| Jan 16, 2026 |
| clinicaltrials |
| NCT05222555 | Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients(MINDway) | active not recruiting | Phase 1 / Phase 2 | 53 | Incyte CorporationINDUSTRY | 9 | Jan 16, 2026 | clinicaltrials |
| NCT01808599 | Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma | active not recruiting | Phase 2 | 112 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 3 | Jan 15, 2026 | clinicaltrials |
| NCT05716087 | A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma | active not recruiting | Phase 2 | 62 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Jan 15, 2026 | clinicaltrials |
| NCT03030261 | Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma | active not recruiting | Phase 2 | 25 | Washington University School of MedicineOTHER | 2 | Jan 12, 2026 | clinicaltrials |
| NCT03278782 | Study of Pembrolizumab (MK-3475) in Combination With Romidepsin | active not recruiting | Phase 1 / Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT01746849 | Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation | active not recruiting | Phase 2 | 82 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04572763 | Copanlisib Plus Venetoclax in R/R DLBCL | active not recruiting | Phase 1 / Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03674411 | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | active not recruiting | Phase 2 | 22 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03961672 | Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 15 | City of Hope Medical CenterOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05952037 | A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia | active not recruiting | Phase 2 | 114 | BeOne MedicinesINDUSTRY | 9 | Jan 2, 2026 | clinicaltrials |
| NCT04604067 | Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial. | active not recruiting | Phase 2 | 260 | Swiss Cancer InstituteOTHER | 2 | Dec 30, 2025 | clinicaltrials |
| NCT05704049 | A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma(IZALCO) | active not recruiting | Phase 2 | 118 | SanofiINDUSTRY | 7 | Dec 29, 2025 | clinicaltrials |
| NCT05130827 | Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT) | active not recruiting | Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT04009109 | Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | active not recruiting | Phase 2 | 79 | Alliance Foundation Trials, LLC.OTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05801939 | Cevostamab Following CAR T Cell Therapy for RRMM | active not recruiting | Phase 2 | 30 | University of PennsylvaniaOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05410418 | Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma | active not recruiting | Phase 2 | 34 | Washington University School of MedicineOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT03620903 | Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia | active not recruiting | Phase 2 | 53 | Christian BuskeOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05065554 | ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy | active not recruiting | Phase 2 | 12 | Shayna Sarosiek, MDOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT03618537 | Ixazomib Maintenance Study in Patients With AL Amyloidosis | active not recruiting | Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04174196 | A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma | active not recruiting | Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT04787263 | CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML | active not recruiting | Phase 1 / Phase 2 | 32 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT02570542 | Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) | active not recruiting | Phase 2 | 59 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07247383 | Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma | active not recruiting | Phase 2 | 39 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT04060277 | Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation | active not recruiting | Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT02253316 | Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma | active not recruiting | Phase 2 | 236 | Washington University School of MedicineOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT02979522 | A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 59 | TakedaINDUSTRY | 4 | Nov 10, 2025 | clinicaltrials |
| NCT04148430 | A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy | active not recruiting | Phase 2 | 62 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT04245839 | A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)(TRANSCEND FL) | active not recruiting | Phase 2 | 276 | CelgeneINDUSTRY | 10 | Nov 5, 2025 | clinicaltrials |
| NCT03315026 | Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis | active not recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT05565417 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | active not recruiting | Phase 1 / Phase 2 | 67 | Immunitas TherapeuticsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT07199855 | Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia | active not recruiting | Phase 2 | 24 | Zhejiang UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT03147885 | Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 43 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT04479267 | Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma | active not recruiting | Phase 2 | 8 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT05192486 | A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) | active not recruiting | Phase 1 / Phase 2 | 12 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05485753 | A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) | active not recruiting | Phase 1 / Phase 2 | 7 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05627856 | A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL | active not recruiting | Phase 1 / Phase 2 | 4 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT02758717 | Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma | active not recruiting | Phase 2 | 46 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT05788081 | Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.(TOP-FLOR) | active not recruiting | Phase 2 | 40 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT03314181 | A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 2 | 156 | AbbVieINDUSTRY | 7 | Aug 14, 2025 | clinicaltrials |
| NCT02734771 | A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)(BV mini CHP) | active not recruiting | Phase 2 | 24 | Patrick ReaganOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT02790515 | Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation | active not recruiting | Phase 2 | 170 | St. Jude Children's Research HospitalOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT03314636 | Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.(CONPET) | active not recruiting | Phase 2 | 53 | Oslo University HospitalOTHER | 3 | Aug 8, 2025 | clinicaltrials |
| NCT02899052 | Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) | active not recruiting | Phase 2 | 120 | AbbVieINDUSTRY | 5 | Aug 5, 2025 | clinicaltrials |
| NCT05860036 | A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma | active not recruiting | Phase 2 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT04052880 | Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM | active not recruiting | Phase 2 | 17 | Larysa SanchezOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06220097 | Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies | active not recruiting | Phase 2 | 28 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT05123131 | Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma(Isa-RVD) | active not recruiting | Phase 2 | 54 | Cancer Trials IrelandNETWORK | 2 | Jul 8, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 22, 2026source: clinicaltrials